Mydocalm tablets 150mg #30

Mydocalm tablets 150mg #30
Manufactured by: Hungary
Product Code: 9416

Qty:  BUY
You can buy Mydocalm tablets 150mg #30 here.

Pharmacological action
Centrally acting muscle relaxant. The mechanism of action is not fully understood. It has a membrane-stabilizing, local anesthetic effect, slows conduction of impulses in primary afferent fibers and motor neurons, leading to blockage of spinal mono-and polysynaptic reflexes. Probably also inhibits the release of secondary mediators by inhibiting Ca2 + inflow into synapses. In the brain stem eliminates facilitation of excitation in reticulospinal path. Enhances peripheral blood flow independent of the effects of CNS. In the development of this effect acts as a weak and antispasmodic effect adrenoblokiruyuschim tolperisone.
After oral tolperisone well absorbed from the gastrointestinal tract. Cmax achieved within 0.5-1 hours Bioavailability - about 20%.
Metabolism and excretion
Tolperisone is metabolized in the liver and kidneys. The pharmacological activity of metabolites is unknown. Excreted by the kidneys as metabolites (99%).
Set individually depending on the clinical picture and tolerability.
Adults appoint 50 mg 2-3 times / day, gradually increasing the dose to 150 mg / day 2-3 times / day.
Tablets are taken after meals, without chewing, with some water.
For children aged 1 to 6 years Midokalm ® is administered orally at a daily dose of 5 mg / kg (3 hours during the day), at the age of 7-14 years - a daily dose of 2-4 mg / kg in 3 divided doses . Film coated tablet should be rubbed, if the child can not swallow it. For children only allowed the use of coated tablets, 50 mg.
Symptoms: Data Mydocalm overdose has been reported. Midokalm ® has a wide therapeutic index, described the case of a child of the drug orally at a dose of 600 mg without causing severe toxic symptoms. While taking the drug orally at a dose of 300-600 mg / day for a child in some cases observed irritability.
In conducting preclinical studies of acute toxicity in animals when high doses were observed ataxia, tonic-clonic seizures, shortness of breath and respiratory paralysis.
Treatment: No specific antidote, recommended gastric lavage, general symptomatic and supportive care.
Drug Interactions
Interaction data that restrict Mydocalm not available.
With simultaneous use Midokalm ® niflumic acid enhances the action, so if you must use this combination to reduce the dose of niflumic acid.
Although tolperisone has an effect on the central nervous system, the drug does not cause sedation, so you might be used in combination with sedatives, hypnotics, and preparations containing ethanol.
No effect on the action of ethanol on the CNS.
General anesthetics, peripheral muscle relaxants, psychiatric drugs enhance the effects of clonidine tolperisone.
Pregnancy and lactation
Application Mydocalm during pregnancy (especially in I trimester) and lactation (breastfeeding) is only possible when the intended benefits to the mother outweighs the potential risk to the fetus or infant.
Side effects
From the digestive system: nausea, vomiting, discomfort in the abdomen.
CNS: headache.
Allergic reactions: rarely - itching, erythema, urticaria, angioedema, anaphylactic shock, bronchospasm.
Other: muscle weakness, hypotension.
As the dose side effects usually go away.
Conditions and terms
List B. The drug should be stored in a dry place away from children, at temperatures from 15 ° to 30 ° C. Shelf life - 3 years.
- Abnormally high tone, spasms of the striated muscles arising from organic neurological disease (pyramidal tract lesions, multiple sclerosis, myelopathy, encephalomyelitis, stroke);
- Abnormally high tone, muscle spasms, muscle contractions that accompany diseases of the musculoskeletal (spondylosis, spondylarthrosis, cervical and lumbar syndrome, arthritis of large joints);
- Medical rehabilitation after orthopedic and trauma operations;
- In a combination therapy of obliterating diseases of blood vessels (arteriosclerosis obliterans, diabetic angiopathy, thromboangiitis obliterans, Raynaud's disease);
- As part of combination therapy of diseases that develop on the basis of violations of vascular innervation (acrocyanosis, intermittent angioneurotic disbaziya);
- Spastic cerebral palsy (Little's disease) and other encephalopathy, accompanied by muscular dystonia.
- Myasthenia gravis;
- Children up to age 1 year;
- Hypersensitivity to the drug.
Effects on ability to drive vehicles and management mechanisms
Use of the drug has no effect on patients' ability to perform work that requires attention and speed of psychomotor reactions.

Write a review

Note: this form is for product reviews only. To contact us please use contact page.

Your Name:

Your Review: Note: HTML is not translated!

Rating: Bad            Good

Enter the code in the box below: